Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 7;9(9):3246-57.
doi: 10.1039/c0ob00768d. Epub 2011 Mar 23.

Design, synthesis and biological characterization of novel inhibitors of CD38

Min Dong  1 , Yuan-Qi Si, Shuang-Yong Sun, Xiao-Ping Pu, Zhen-Jun Yang, Liang-Ren Zhang, Li-He Zhang, Fung Ping Leung, Connie Mo Ching Lam, Anna Ka Yee Kwong, Jianbo Yue, Yeyun Zhou, Irina A Kriksunov, Quan Hao, Hon Cheung Lee
Affiliations

Design, synthesis and biological characterization of novel inhibitors of CD38

Min Dong et al. Org Biomol Chem. .

Abstract

Human CD38 is a novel multi-functional protein that acts not only as an antigen for B-lymphocyte activation, but also as an enzyme catalyzing the synthesis of a Ca(2+) messenger molecule, cyclic ADP-ribose, from NAD(+). It is well established that this novel Ca(2+) signaling enzyme is responsible for regulating a wide range of physiological functions. Based on the crystal structure of the CD38/NAD(+) complex, we synthesized a series of simplified N-substituted nicotinamide derivatives (Compound 1-14). A number of these compounds exhibited moderate inhibition of the NAD(+) utilizing activity of CD38, with Compound 4 showing the highest potency. The crystal structure of CD38/Compound 4 complex and computer simulation of Compound 7 docking to CD38 show a significant role of the nicotinamide moiety and the distal aromatic group of the compounds for substrate recognition by the active site of CD38. Biologically, we showed that both Compounds 4 and 7 effectively relaxed the agonist-induced contraction of muscle preparations from rats and guinea pigs. This study is a rational design of inhibitors for CD38 that exhibit important physiological effects, and can serve as a model for future drug development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inhibitors of CD38
Figure 2
Figure 2
NAD+ and N-aromatic ether substituted nicotinamides.
Figure 2
Figure 2
NAD+ and N-aromatic ether substituted nicotinamides.
Figure 3
Figure 3
Biological effects of compounds 4, 7 and 9 on agonist-induced muscle contraction. A. Concentration–response curves for solvent (MQ water) control, compound 4 (active) and compound 9 (inactive), on the phenylephrine-induced vascular contraction in isolated rat aortic ring preparations. B. Nicotinamide, a commonly used inhibitor of CD38 induced similar vascular relaxation. Results are means±S.E.M. using tissues from three to five rats in each group. C. The relaxing effects of Compounds 4 and 7 on the acetylcholine-induced contraction in isolated tracheal strips of guinea pigs. Data represent the mean ± SEM (n= 7). *P<0.05, statistically significant as compared with Krebs-Henseleit solution group.
Figure 4
Figure 4. Structural alignment between CD38-Compound 4 and CD38-NAD complexes
(A) Surface presentation of the active pocket of CD38 (palegreen). NAD (sticks presentation in magentas) penetrated to the bottom of the active pocket of CD38, while compound 4 (sticks presentation in grey) floated over the active site. (B) The nicotinamide group of both compound 4 (grey) and NAD (magentas) is similarly positioned and stabilized by the interactions with residue Glu146, Asp155 and Trp189 of CD38.
Figure 5
Figure 5
a) The molecular dynamics simulation binding mode of compound 7 in the active pocket of human CD38. The carbon atoms of 7 are indicated in cyan. All the nitrogen atoms are blue; oxygen atoms are red. Hydrogen bonds are represented by blue dotted lines. Corresponding residues are labeled and shown in blue lines. b) Superimposition the binding poses of compound 4 in the enzyme-inhibitor cyrastal with molecular dynamics simulation result of 7. 4 is shown as magenta stick; 7 is shown as cyan stick.
Scheme 1
Scheme 1
Synthesis of analogues 1 and 2.
Scheme 2
Scheme 2
Synthesis of analogues 3–7.
Scheme 3
Scheme 3
Synthesis of analogues 12
Scheme 4
Scheme 4
Synthesis of 8–11.
Scheme 5
Scheme 5
Synthesis of analogues 13 and 14.
See this image and copyright information in PMC

References

    1. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc. Natl. Acad. Sci. U. S. A. 1980;77:1588–1592. - PMC - PubMed
    1. Lee HC. Enzymatic functions and structures of CD38 and homologs. Chem. Immunol. 2000;75:39–59. - PubMed
    1. Lee HC. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Ann. Rev. Pharmacol. Toxicol. 2001;41:317–345. - PubMed
    2. Lee HC, Aarhus R, Levitt D. The crystal structure of cyclic ADP-ribose. Nat. Struct. Biol. 1994;1:143–144. - PubMed
    3. Lee HC, Walseth TF, Bratt GT, et al. Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. J. Biol. Chem. 1989;264:1608–15. - PubMed
    1. Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;262:1056–1059. - PubMed
    1. Kato I, Yamamoto Y, Fujimura M, Noguchi N, Takasawa S, Okamoto H. CD38 disruption impairs glucose-induced increases in Cyclic ADP-ribose, [Ca2+]i, and insulin secretion. J. Biol. Chem. 1999;274:1869–1872. - PubMed

Publication types

Substances